| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999293 | Urologic Oncology: Seminars and Original Investigations | 2016 | 9 Pages |
Abstract
Our current data support recent observations indicating the involvement of the AR pathway in bladder cancer growth and further suggest that AR antagonists, including enzalutamide, are of therapeutic benefit in AR-positive bladder cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Takashi M.D., Hiroki M.D., Eiji M.D., Ph.D., Kareem A. M.D., Yi M.D., Leonardo O. M.D., Ph.D., Yichun M.D., Ph.D., Hiroshi M.D., Ph.D.,